Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.
Conflict with name of patents for grapes and cherries prompts denial | If permitted, mark would “impede free use in the marketplace of a varietal denomination” following the patent’s expiration.
Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Life sciences practice boosted by four-partner ‘powerhouse’ team | Attorneys have all achieved notable trial outcomes for pharma companies.
Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.
Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.
Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.